In the meantime, Citigroup initiated its Structure Therapeutics Inc ADR [GPCR] rating to a Buy in a research note published on May 02, 2025; the price target was $60. A number of analysts have revised their coverage, including William Blair’s analysts, who began to cover the stock in late February with a ‘”an Outperform”‘ rating. Stifel began covering GPCR with “Buy” recommendation on January 08, 2025. H.C. Wainwright started covering the stock on December 04, 2024. It rated GPCR as “a Buy”.
Price Performance Review of GPCR
On Tuesday, Structure Therapeutics Inc ADR [NASDAQ:GPCR] saw its stock fall -8.04% to $25.33. Over the last five days, the stock has lost -2.24%. Structure Therapeutics Inc ADR shares have fallen nearly -6.60% since the year began. Nevertheless, the stocks have fallen -35.03% over the past one year. While a 52-week high of $62.74 was reached on 01/31/25, a 52-week low of $13.22 was recorded on 04/09/25. SMA at 50 days reached $20.98, while 200 days put it at $31.04.
Levels Of Support And Resistance For GPCR Stock
The 24-hour chart illustrates a support level at 24.47, which if violated will result in even more drops to 23.60. On the upside, there is a resistance level at 26.99. A further resistance level may holdings at 28.64. The Relative Strength Index (RSI) on the 14-day chart is 61.12, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.30, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 31.19%. Stochastics %K at 81.62% indicates the stock is a selling.
The most recent change occurred on September 23, 2024 when Morgan Stanley began covering the stock and recommended ‘”an Overweight”‘ rating along with a $118 price target.
